run coming?, page-51

Just playing with some of the figures from today's presentation.

In the benchmark study 41% of patients fully healed.

In our current one it's currently 53%.

If we assume in our study that the placebo's third is similar to the benchmark study, then the two thirds on our drug have a full healing rate of 60%.

60% compared to 41% is nearly a 50% improvement over the benchmark, which is a hugely statistically significant benefit.

ok, there is the assumption that the placebo mirrors the benchmark result - but that's all we have to go on at the moment.

Cheers